Hepion Pharmaceuticals names James Liddy to board

• Hepion Pharmaceuticals appointed James Liddy to its board, effective Aug. 19, 2026.
• The filing disclosed no selection arrangements tied to Liddy.
• No reportable related-party transactions involving Liddy were identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039488), on August 20, 2026, and is solely responsible for the information contained therein.